These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30910434)

  • 1. Vestibulotoxicity in a patient without renal failure after inhaled tobramycin.
    Kaufman AC; Eliades SJ
    Am J Otolaryngol; 2019; 40(3):456-458. PubMed ID: 30910434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency.
    Edson RS; Brey RH; McDonald TJ; Terrell CL; McCarthy JT; Thibert JM
    Mayo Clin Proc; 2004 Sep; 79(9):1185-91. PubMed ID: 15357042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.
    Ahya VN; Doyle AM; Mendez JD; Lipson DA; Christie JD; Blumberg EA; Pochettino A; Nelson L; Bloom RD; Kotloff RM
    J Heart Lung Transplant; 2005 Jul; 24(7):932-5. PubMed ID: 15982625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vestibulotoxicity as a consequence of systemically administered tobramycin in cystic fibrosis patients.
    Scheenstra RJ; Rijntjes E; Tavy DL; Kingma H; Heijerman HG
    Acta Otolaryngol; 2009 Jan; 129(1):4-7. PubMed ID: 18607923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with Pseudomonas aeruginosa.
    Izquierdo MJ; Gomez-Alamillo C; Ortiz F; Calabia ER; Ruiz JC; de Francisco AL; Arias M
    Clin Nephrol; 2006 Dec; 66(6):464-7. PubMed ID: 17176920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute renal failure associated with inhaled tobramycin.
    Cannella CA; Wilkinson ST
    Am J Health Syst Pharm; 2006 Oct; 63(19):1858-61. PubMed ID: 16990632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy.
    Hoffmann IM; Rubin BK; Iskandar SS; Schechter MS; Nagaraj SK; Bitzan MM
    Pediatr Pulmonol; 2002 Nov; 34(5):375-7. PubMed ID: 12357482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum tobramycin concentrations after treatment with tobramycin inhalation in a preterm infant.
    Abdulhamid I; Wise TL; Andrews S; Biglin K; Lehr VT
    Pharmacotherapy; 2008 Jul; 28(7):939-44. PubMed ID: 18576909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa.
    Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R
    Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
    Patatanian L
    Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible tobramycin-induced bilateral high-frequency vestibular toxicity.
    Walsh RM; Bath AP; Bance ML
    ORL J Otorhinolaryngol Relat Spec; 2000; 62(3):156-9. PubMed ID: 10810261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis.
    Regnault A; Balp MM; Kulich K; Viala-Danten M
    J Cyst Fibros; 2012 Dec; 11(6):494-501. PubMed ID: 22583743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.
    Stanojevic S; Waters V; Mathew JL; Taylor L; Ratjen F
    J Cyst Fibros; 2014 Mar; 13(2):172-8. PubMed ID: 24091166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia.
    Arnold HM; Sawyer AM; Kollef MH
    Respir Care; 2012 Aug; 57(8):1226-33. PubMed ID: 22349038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Use of inhaled tobramycin in patients with cystic fibrosis].
    Chermenskiĭ AG; Gembitskaia TE
    Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled tobramycin solution-associated recurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis: a case report.
    Santos RP; Awa E; Anbar RD
    BMC Pediatr; 2007 Mar; 7():11. PubMed ID: 17331261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study.
    Hallal A; Cohn SM; Namias N; Habib F; Baracco G; Manning RJ; Crookes B; Schulman CI
    Surg Infect (Larchmt); 2007 Feb; 8(1):73-82. PubMed ID: 17381399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.